Tag: Harbour BioMed
-
Harbour BioMed and Lannacheng Advance Radionuclide Drug Conjugates
Harbour BioMed and Lannacheng Forge a Long-Term Strategic Collaboration Harbour BioMed has entered into a long-term strategic collaboration with Lannacheng to accelerate the discovery and development of next-generation radionuclide drug conjugates (RDCs). The partnership, announced by Harbour BioMed and Lannacheng, signals a shared commitment to advancing radiopharmaceuticals that combine targeted antibodies with radionuclide therapy to…
-
Radionuclide Drug Conjugates: Harbour BioMed & Lannacheng Alliance
Harbour BioMed and Lannacheng Forge a Long-Term Strategic Collaboration In a bold move to accelerate precision oncology, Harbour BioMed and Lannacheng have announced a long-term strategic collaboration focused on the development of next-generation radionuclide drug conjugates (RDCs). The partnership appears to align with a broader industry trend toward targeted radiopharmaceuticals that combine the specificity of…
-
Harbour BioMed and Lannacheng Forge Long-Term Strategic Collaboration to Accelerate Radionuclide Drug Conjugates
Strategic Collaboration Aims to Accelerate Radionuclide Drug Conjugates Harbour BioMed has announced a long-term strategic collaboration with Lannacheng to accelerate the discovery and development of next-generation radionuclide drug conjugates (RDCs). The partnership combines Harbour BioMed’s expertise in antibody therapeutics with Lannacheng’s strength in radiopharmaceutical science, creating a powerful platform to target difficult-to-treat cancers and inflammatory…